2 completed. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow LY900003: new trials by email Literature Review of LY900003 trials Research Report on LY900003
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer. Gemcitabine, Carboplatin, LY900003 - Carcinoma, Non-Small-Cell Lung, Pulmonary Neoplasms | Phase 2 | Completed | Eli Lilly and Company | 2002-06-01 | 2006-07-19 | |
| A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer LY900003 - Carcinoma, Non-Small-Cell Lung | Phase 3 | Completed | Eli Lilly and Company | 2002-03-01 | 2006-07-19 |
Carcinoma, Non-Small-Cell Lung (2) · Adenocarcinoma (1) · Carcinoma, Squamous Cell (1) · Lung Neoplasms (1)
United States (2) · Argentina (1) · Belgium (1) · Chile (1) · France (1) · Germany (1) · Hungary (1) · India (1) · Italy (1) · Netherlands (1) · Norway (1) · Poland (1) · Puerto Rico (1) · Romania (1) · Russia (1)